Research programme: cholesterol-lowering therapies - Medicure/Universities of Manitoba and Ottawa Heart Institute
Latest Information Update: 02 May 2007
At a glance
- Originator University of Manitoba; University of Ottawa Heart Institute
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 31 Jan 2005 Preclinical trials in Hypercholesterolaemia in Canada (unspecified route)